article thumbnail

SGLT-2 inhibitor, cardiovascular risk and outcome in patients with comorbidity of hypertension and diabetes [Cardiovascular disease]

Annals of Family Medicine

Context Two thirds of diabetes patients complicated with hypertension, and comorbidity increase 4-fold risk of atherosclerotic cardiovascular disease (ASCVD). Population Studied individuals with comorbidity of hypertension and type 2 diabetes. Outcome Measures Changes of China-PAR score and cardiovascular hospitalization events.

article thumbnail

Contraceptive counseling for gender-diverse patients: A community needs assessment [Health care disparities]

Annals of Family Medicine

Context: Sexual- and gender-minority (SGM) patients face high rates of discrimination, bias, and gender dysphoria when seeking care, including when seeking contraception. Additionally, the majority wanted the decision-aid to be inclusive of both gender-diverse and non-gender-diverse individuals.

Community 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Should We Screen for Atrial Fibrillation? ESC Says Yes (2024), Evidence Says…?

Family Medicine Initiative

ACC/AHA/ACCP/HRS Guideline (2023): “It is not yet established that patients at high risk of developing AF by a validated risk score benefit from screening.” Although not a guideline, still relevant: The German Arznei-Telegramm concluded in 2021, 2023, and 2024 that atrial fibrillation screening is not recommended in asymptomatic individuals.

Screening 130
article thumbnail

Delayed SEC Access and Survival in axSpA

Physician's Weekly

Secukinumab showed moderate effectiveness but delayed access and reduced survival in later-line use, especially among publicly insured patients. They assessed patients aged ≥ 18 years with axSpA or axPsA who received ≥ 1 dose of SEC. events per 100 patients per year [95% CI 5–12]. The incidence of AEs was 7.9

article thumbnail

FDA Approves Dupixent for Bullous Pemphigoid

Physician's Weekly

Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. Patients with moderate-to-severe bullous pemphigoid were randomly assigned to receive Dupixent 300 mg (53 individuals) or placebo (53 individuals) added to standard-of-care oral corticosteroids.

article thumbnail

Natural History of Asymptomatic Renal Stones Before RC

Physician's Weekly

Researchers conducted a retrospective study to examine the outcomes and natural history of asymptomatic renal stones managed by observation following RC and UD. They reviewed individuals referred for RC and UD between 2015 and 2023 at a single center. Preoperative CT scans were analyzed to identify those with asymptomatic renal stones.

article thumbnail

Well-being Investment: Movement & Exercise

Joy in Family Medicine Coaching

You Know This - still - it’s a good time to review through the lens of self instead of patient care. Lower risks of cardiovascular events and all-cause mortality. For very sedentary individuals every step above 2,200 steps is beneficial. Last week we reviewed a helpful lifestyle change framework.